Ultragenyx Pharmaceutical Inc. (RARE)
NEUTRALFundamental
34
मूल्य
$26.13
मार्केट कैप
$2.54B
भाग 1 · कंपनी का मूल्य कितना है
अवलोकन
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidates that are in Phase 3 clinical trials include UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; and GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome. It also develops UX701, an adeno-associated AAV9 gene therapy which is in Phase 2 clinical trial for the treatment of Wilson liver disease. The company has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; GeneTx; Mereo; University of Pennsylvania; Regeneron; and Abeona. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
बैलेंस शीट और तरलता
राजस्व
$717M
पिछले 12 महीने (30/6/2026 तक)
शुद्ध आय
$-586M
पिछले 12 महीने (30/6/2026 तक)
Free Cash Flow
$-472M
कुल इक्विटी
$-80M
कुल देनदारियाँ
$1.60B
Current Ratio
1.73
Interest Coverage
-
Debt/EBITDA
-
Earnings Per Share
राजस्व और शुद्ध आय
Free Cash Flow
आय विवरण
ऐतिहासिक विवरण
समय के साथ मार्जिन
समय के साथ ऋण
ऋण कितना भारी है
वृद्धि तालिका
वृद्धि — राजस्व
Fair Value अनुमान
Fair Value
$54.79
वर्तमान मूल्य
$26.13
Margin of Safety
+52.3%
Fair Value सीमा
$52.05 - $57.53
अनुमान विधियाँ
मूल्यांकन मेट्रिक्स
P/E Ratio
-
ROE
718.8%
P/B Ratio
-
P/FCF
-
Gross Margin
-
ROIC
-45.7%
लाभप्रदता Radar
Value Creation (Economic Moat)
ROIC
-45.7%
WACC
5.5%
ROIC − WACC
-51.2 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Fundamental विश्लेषण मानदंड
पास (5)
- EPS shows upward trend
- Current Ratio
- Revenue Growth 5Y 19.9%
- Analyst Consensus 88% Buy
- Net Margin Trend -81.7% vs -87.3%
फेल (11)
- Price CAGR -9.53%
- ROIC -45.7%
- Operating Margin -73.6%
- Positive Free Cash Flow
- Return on Tangible Assets
- Low reliance on intangibles
- DCF valuation (Unknown)
- ROE -414.2%
- Earnings Surprise avg -12.9%
- Share Dilution 9.0%
- Piotroski F-Score 4/9
अनुपलब्ध (11)
- Gross Margin NaN%
- P/FCF NaN
- P/B Ratio NaN
- Dividend Payout NaN%
- Debt/Equity ratio
- CapEx intensity
- Interest Coverage
- Debt/EBITDA
- Price below Graham Number
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
Piotroski F-Score
मिश्रित संकेत: कुछ क्षेत्रों पर ध्यान देना आवश्यक
Earnings गुणवत्ता
निम्न गुणवत्ता: accounting की जांच करें
शेयर Dilution
नए शेयर जारी कर रही है, स्वामित्व को कम कर रही है
प्रशासन
कार्यकारी टीम
| नाम | पद | आयु |
|---|---|---|
| Dr. Emil D. Kakkis M.D., Ph.D. | Founder, President, CEO & Director | 65 |
| Mr. Howard Horn | Executive VP of Corporate Strategy & CFO | 46 |
| Ms. Karah Herdman Parschauer J.D. | Chief Legal Officer & Executive VP of Corporate Affairs | 47 |
| Mr. Erik Harris M.B.A. | Executive VP & Chief Commercial Officer | 55 |
| Dr. Eric Crombez M.D. | Chief Medical Officer & Executive VP | 52 |
| Mr. Theodore A. Huizenga | Senior VP, Corporate Controller & Principal Accounting Officer | 54 |
| Mr. Ernie W. Meyer | Chief Human Resources Officer & Executive VP | 60 |
| Mr. Vimal Srivastava | Senior Vice President of Business Development & Alliance Management | 60 |
| Mr. John Richard Pinion II | Chief Quality Operations Officer & Executive VP of Translational Sciences | 59 |
| Aaron Olsen | Senior Vice President of Corporate Strategy & Finance | - |
Audit जोखिम
5
बोर्ड जोखिम
2
मुआवजा जोखिम
8
शेयरधारक अधिकार जोखिम
7
भाग 2 · कीमत और खरीदने का समय
यह हिस्सा यह नहीं बताता कि कंपनी अच्छी है या नहीं: यह तय करने में मदद करता है कि उसे कब खरीदें, जब फंडामेंटल आपको आश्वस्त कर चुके हों। इसमें: तकनीकी विश्लेषण, संभावना, ऐतिहासिक गिरावट, गामा एक्सपोज़र।
Latest News
Recent headlines for RARE, sourced from Markets Gazette.
- 3/12/2026POSITIVEUltragenyx's Gene Therapy Study Shows Ammonia Reduction In Rare Metabolic Disorder
Ultragenyx Pharmaceutical Inc. announced positive Phase 3 data for its gene therapy candidate, demonstrating a significant reduction in ammonia levels for patients with a rare metabolic disorder. While full clinical outcomes are anticipated in 2027, the early success in normalizing key biomarkers offers a promising outlook. This development could position Ultragenyx as a leader in treating ultra-rare genetic diseases, potentially leading to substantial market share and improved patient lives, which is a strong signal for investors.
via Markets Gazette